Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term BBP-418 (ribitol) extension study in LGMD2I/R9
NL-OMON61246Phase 3Not yet recruiting
- Sponsor
- ML Bio Solutions
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ribitol in limb-girdle muscular dystrophy type 2I (LGMD2I), sponsored by ML Bio Solutions. Primary endpoints: Frequency and severity of TEAEs and treatment-emergent SAEs and Change from baseline in NSAD at EOT. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ribitol
03
Conditions
limb-girdle muscular dystrophy type 2I (LGMD2I)
Beyond the preview
Go deeper on NL-OMON61246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61246.